Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies

Leukemia

Volumn 19, Issue 2, 2005, Pages 268-274

  Wu, F ^a   Oka, Y ^a   Tsuboi, A ^a   Elisseeva, O A ^a   Ogata, K ^b   Nakajima, H ^a   Fujiki, F ^a   Masuda, T ^a   Murakami, M ^a   Yoshihara, S ^a   Ikegame, K ^a   Hosen, N ^a   Kawakami, M ^a   Nakagawa, M ^c   Kubota, T ^d   Soma, T ^e   Yamagami, T ^e   Tsukaguchi, M ^f   Ogawa, H ^a   Oji, Y ^a   Hamaoka, T ^a   Kawase, I ^a   Sugiyama, H ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Nippon Life Saiseikai Foundation   (Japan)

^d Tondabayashi Hospital   (Japan)

^e MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^f SAKAI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Cancer immunotherapy; Humoral immune response; lgG subclass; Th1; Wilms' tumor gene (WT1)

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN SUBCLASS; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; TH1 CELL; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VOLUNTEER;

EID: 13544277152     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403539     Document Type: Article

References (35)

1. Call KM, Glaser T, Ito CY. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms' tumors of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-778.
3. Haber DA, Park S, Maheswaran S. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 1993; 262: 2057-2059.
4. Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y, Smith PJ. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumor associated with high levels of expression of a truncated transcript. Hum Mutat 1995; 5: 221-227.
5. Sugiyama H. Wilm's tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73: 177-187.
6. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
7. Tamaki H, Ogawa H, Ohyashiki K, Tamaki H, Ogawa H, Ohyashiki K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393-399.
8. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH et al. Expression of the Wilm's tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204.
9. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8: 1167-1171.
10. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. Growth inhibition of human leukemic cells by WT1 (Wilms' tumor gene) antisense oligodeoxynucleotides; implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878-2884.
11. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
12. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
13. Oka Y, Elisseeva. OA, Tsuboi A, Ogawa H, Tamaki H, Li H et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
14. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-293.
15. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
16. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-620.
17. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J immunol 2000; 15: 1873-1880.
18. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000; 20: 195-202.
19. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.
20. Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001; 7: 761-765.
21. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms' tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-3279.
22. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
23. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704.
24. Gupta RK, Siber GR. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay. J Immunol Methods 1995; 181: 75-81.
25. Gupta CK, Leszczynski J, Gupta RK, Siber GR. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Biologicals 1996; 24: 117-124.
26. Hamilton RG, Adkinson Jr NF. Quantitative aspects of solid phase immunoassays. In: Kemeny DM, Challacombe SJ (eds). Theoretical and Technical Aspects of ELISA and Other Solid Phase Immunoassays,, Vol. 3. New York: John Wiley & Sons, 1988, pp 57-84.
27. Naess LM, Rosenqvist E, Hoiby EA, Michaelsen TE. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods 1996; 196: 41-49.
28. Xu H, Lohr J, Greiner M. The selection of ELISA cut-off points for testing antibody to Newcastle disease by two-graph receiver operating characteristic (TG-ROC) analysis. J Immunol Methods 1997; 208: 61-64.
29. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
30. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK et al. Survey of maturally occurring CD4+ T-cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 8862-8867.
31. Amyes E, Curnow J, Stark Z, Corlett L, Sutton I, Vincent A. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2001; 114: 259-264.
32. Hussain R, Dockrell HM, Chiang TJ. IgG subclass antibody to Mycobacterium leprae 18000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Immunology 1994; 83: 495-500.
33. Ng WY, Thai AC, Lui KF, Yeo PP, Cheah JS. Systemic levels of cytokines and GAD-specific autoantibody isotypes in Chinese IDDM patients. Diabetes Res Clin Pract 1999; 43: 127-135.
34. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, et al., for the French Asymptomatic Long-Term Study Group. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 2001; 15: 1435-1446.
35. Skyllouriotis P, Skyllouriotis-Lazarou M, Natter S, Steiner R, Spitzauer S, Kapiotis S et al. IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune. Clin Exp Immunol 1999; 115: 236-247.